Heart Sounds Measurement Using The Wearable Cardioverter Defibrillator In Hospitalized Acute Heart Failure Patients

Overview

About this study

A study to evaluate the changes in heart sounds measurements recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD) during the medical treatment of hospitalized acute heart failure (AHF) patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients who are 18 years of age or older on the day of screening.
  • Patients who are admitted to the hospital with a diagnosis of AHF.
  • Included within this group are no more than 3 patients with a known history of atrial fibrillation.
  • Patients who have an ejection fraction (EF) ≤ 35% as evidenced by an echocardiogram from the current index presentation or within the last 30 days.
  • Patients who are able to be fit with a WCD within 24 hours (ideally within 6 hours) of hospital admission.
  • Patients who are able to be fit in the WCD garment (26 to 56 inches measured circumferentially at the level of the xiphoid process).
  • Patients who are willing to wear the WCD up to hospital discharge or for a maximum 7 days, whichever occurs first.
  • Patients who are willing to continue wearing the WCD for 5 days post-discharge from the hospital.

Exclusion Criteria:

  • Patients with evidence of pacing on their admission ECG.
  • Patients with cardiac resynchronization therapy device.
  • Patients with an implantable cardioverter defibrillator.
  • Patients with left ventricular assistive device.
  • Patients with heart transplant.
  • Patients with acute myocardial infarction diagnosed in the emergency department or at admission.
  • Patients who are currently on dialysis or who may undergo ultrafiltration during the index hospitalization.
  • Patients who are pregnant.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Bruce Johnson, Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20385604

Mayo Clinic Footer